Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone®) increases antibody response, cellular immunity, and antigenically drifted protection

Vaccine

Volumn 27, Issue 29, 2009, Pages 3811-3820

  Lay, Marla ^a   Callejo, Bernadette ^a   Chang, Stella ^a   Hong, David K ^b   Lewis, David B ^b   Carroll, Timothy D ^c   Matzinger, Shannon ^c   Fritts, Linda ^c   Miller, Christopher J ^c   Warner, John F ^a   Liang, Lily ^a   Fairman, Jeffery ^a  

^a Juvaris BioTherapeutics Inc   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adjuvant; Influenza; Vaccine

Indexed keywords

CHOLESTEROL; DNA; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; JVRS 100; JVRS 100 INFLUENZA VACCINE CONJUGATE; LIPOSOME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG RESPONSE; DRUG SAFETY; GENETIC DRIFT; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA; INFLUENZA A H1N1; INFLUENZA VIRUS B; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; VIRUS STRAIN; WEIGHT REDUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; BODY WEIGHT; DNA; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; LIPOSOMES; MACACA MULATTA; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; VACCINES, SUBUNIT;

EID: 67349263384     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.04.054     Document Type: Article

References (49)

1. Murphy B.R., Kasel J.A., and Chanock R.M. Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med 286 June (25) (1972) 1329-1332
2. Virelizier J.L. Host defenses against influenza virus: the role of anti-hemagglutinin antibody. J Immunol 115 August (2) (1975) 434-439
3. Cox R.J., Brokstad K.A., and Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 59 January (1) (2004) 1-15
4. Hilleman M.R. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine 20 August (25-26) (2002) 3068-3087
5. Clements M.L., Betts R.F., Tierney E.L., and Murphy B.R. Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine. J Clin Microbiol 23 January (1) (1986) 73-76
6. Clements M.L., Betts R.F., Tierney E.L., and Murphy B.R. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 24 July (1) (1986) 157-160
7. Belshe R.B., Gruber W.C., Mendelman P.M., Mehta H.B., Mahmood K., Reisinger K., et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 181 March (3) (2000) 1133-1137
8. Smith H., and Sweet C. Lessons for human influenza from pathogenicity studies with ferrets. Rev Infect Dis 10 January-February (1) (1988) 56-75
9. Doherty P.C., Turner S.J., Webby R.G., and Thomas P.G. Influenza and the challenge for immunology. Nat Immunol 7 May (5) (2006) 449-455
10. Kilbourne E.D. Influenza immunity: new insights from old studies. J Infect Dis 193 January (1) (2006) 7-8
11. McMichael A.J., Gotch F.M., Noble G.R., and Beare P.A. Cytotoxic T-cell immunity to influenza. N Engl J Med 309 July (1) (1983) 13-17
12. Lee L.Y., Do L.H., Simmons C., deJong M.D., Nguyen V.C., Schumacher R., et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 118 October (10) (2008) 3478-3490
13. Benton K.A., Misplon J.A., Lo C.Y., Brutkiewicz R.R., Prasad S.A., and Epstein S.L. Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NK T cells, or gamma delta T cells. J Immunol 166 June (12) (2001) 7437-7445
14. Tumpey T.M., Renshaw M., Clements J.D., and Katz J.M. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 75 June (11) (2001) 5141-5150
15. Epstein S.L. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 193 January (1) (2006) 49-53
16. Steinhoff M.C., Fries L.F., Karron R.A., Clements M.L., and Murphy B.R. Effect of heterosubtypic immunity on infection with attenuated influenza A virus vaccines in young children. J Clin Microbiol 31 April (4) (1993) 836-838
17. Kemble G., and Greenberg H. Novel generations of influenza vaccines. Vaccine 21 May (16) (2003) 1789-1795
18. Beyer W.E., Palache A.M., deJong J.C., and Osterhaus A.D. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 20 October (9-10) (2002) 1340-1353
19. Stephenson I., Zambon M.C., Rudin A., Colegate A., Podda A., Bugarini R., et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 80 May (10) (2006) 4962-4970
20. Subbarao K., Murphy B.R., and Fauci A.S. Development of effective vaccines against pandemic influenza. Immunity 24 January (1) (2006) 5-9
21. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., and Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5 October 10 (1999) 1157-1163
22. Kodihalli S., Kobasa D.L., and Webster R.G. Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines. Vaccine 18 May (23) (2000) 2592-2599
23. Baird M.R., Wilson L., Young L., Williman J., Young S., Wilson M., et al. Bystander help within a polyepitope DNA vaccine improves immune responses to influenza antigens. Scand J Immunol 60 October (4) (2004) 363-371
24. Epstein S.L., Kong W.P., Misplon J.A., Lo C.Y., Tumpey T.M., Xu L., et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23 November (46-47) (2005) 5404-5410
25. Palese P., and Garcia-Sastre A. Influenza vaccines: present and future. J Clin Invest 110 July (1) (2002) 9-13
26. Rimmelzwaan G.F., Claas E.C., vanAmerongen G., deJong J.C., and Osterhaus A.D. ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Vaccine 17 March (11-12) (1999) 1355-1358
27. Gluck R., Mischler R., Durrer P., Furer E., Lang A.B., Herzog C., et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J Infect Dis 181 March (3) (2000) 1129-1132
28. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19 17-19 (2001) 2673-2680
29. Benne C.A., Harmsen M., van der Graaff W., Verheul A.F., Snippe H., and Kraaijeveld C.A. Influenza virus neutralizing antibodies and IgG isotype profiles after immunization of mice with influenza A subunit vaccine using various adjuvants. Vaccine 15 9 (1997) 1039-1044
30. Hayashi M., Satou E., Ueki R., Yano M., Miyano-Kurosaki N., Fujii M., et al. Resistance to influenza A virus infection by antigen-conjugated CpG oligonucleotides, a novel antigen-specific immunomodulator. Biochem Biophys Res Commun 329 April (1) (2005) 230-236
31. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Krieg A.M., Li Y., et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluvarix influenza vaccine. Vaccine 22 August (23-24) (2004) 3136-3143
32. Zaks K., Jordan M., Guth A., Sellins K., Kedl R., Izzo A., et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 176 June (12) (2006) 7335-7345
33. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37 April (4) (1999) 937-943
34. Genesca M., Rourke T., Li J., Bost K., Chohan B., McChesney M.B., et al. Live attenuated lentivirus infection elicits polyfunctional simian immunodeficiency virus Gag-specific CD8+ T cells with reduced apoptotic susceptibility in rhesus macaques that control virus replication after challenge with pathogenic SIVmac239. J Immunol 179 October (7) (2007) 4732-4740
35. Huber V.C., McKeon R.M., Brackin M.N., Miller L.A., Keating R., Brown S.A., et al. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vac Immunol 13 September (9) (2006) 981-990
36. Beebe D.P., Schreiber R.D., and Cooper N.R. Neutralization of influenza virus by normal human sera: mechanisms involving antibody and complement. J Immunol 130 March (3) (1983) 1317-1322
37. Hobson D., Curry R.L., Beare A.S., and Ward-Gardner A. The role of derum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hygn 70 December (4) (1972) 767-777
38. Jegerlehner A., Schmitz N., Storni T., and Bachmann M.E. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 172 May (9) (2004) 5598-5605
39. Dow S.W., Fradkin L.G., Liggitt D.H., Willson A.P., Heath T.D., and Potter T.A. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 163 August (3) (1999) 1552-1561
40. Wack A., Baudner B.C., Hilbert A.K., Manini I., Nuti S., Tavarini S., et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26 January (4) (2008) 552-561
41. Belshe R.B., Mendelman P.M., Treanor J., King J., Gruber W.C., Piedra P., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 338 May (20) (1998) 1405-1412
42. Treanor J.J., Schiff G.M., Hayden F.G., Brady R.C., Hay C.M., Meyer A.L., et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 297 April (14) (2007) 1577-1582
43. Brown D.M., Dilzer A.M., Meents D.L., and Swain S.L. CD4, T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J Immunol 177 September (5) (2006) 2888-2898
44. Mozdzanowska K., Furchner M., Zharikova D., Feng J., and Gerhard W. Roles of CD4+ T-cell-independent and -dependent antibody responses in the control of influenza virus infection: evidence for noncognate CD4+ T-cell activities that enhance the therapeutic activity of antiviral antibodies. J Virol 79 May (10) (2005) 5943-5951
45. Bender B.S., Croghan T., Zhang L., and Small P.A. Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med 175 April (4) (1992) 1143-1145
46. Graham M.B., and Braciale T.J. Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J Exp Med 186 December (12) (1997) 2063-2068
47. Darrah P.A., Patel D.T., DeLuca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13 July (7) (2007) 843-850
48. Seder R.A., Darrah P.A., and Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8 April (4) (2008) 247-258
49. Thomas P.G., Brown S., Wen Y., So J., Webby R., and Doherty P. An unexpected antibody response to an engineered influenza virus modifies CD8+ T cell responses. Proc Natl Acad Sci USA 103 February (8) (2006) 2764-2769